From Bloomberg, May 14:
Sanofi said it will invest at least $20 billion in the US through 2030, joining other pharmaceutical companies boosting their American operations as President Donald Trump threatens to impose tariffs and cut prices on drugs.
The investments will include a “significant increase” in research and development spending and billions of dollars devoted to US manufacturing, the French drugmaker said in a statement
Wednesday. The company didn’t say how much of that will represent new investments versus previous commitments.
Earlier this week Trump signed an executive order to reference drug prices in the US to lower prices paid in other countries.
Swiss drugmaker Roche Holding AG said earlier Wednesday that it would need to reconsider planned US investments of $50 billion announced last month if Trump implements the order, saying it could affect the company’s ability to fund them.
Roche’s rival, Novartis AG, said last month that it plans $23 billion in fresh spending in the US. The Basel, Switzerland-based drugmaker has no plans to change its proposed capital expenditure in the US, according to a statement from the company.
US drugmakers have also announced a series of domestic investments. Eli Lilly & Co. said in February it would spend at least $27 billion on four US plants within the next five years. Merck & Co. has promised to invest more than $9 billion domestically by 2028, while Johnson & Johnson pledged more than $55 billion over the next four years. Earlier this month, Bristol Myers Squibb Co. said it would spend $40 billion in the US over the next five years....
....MUCH MORE
However, also at Bloomberg:
Roche Warns US Investment at Risk From Trump Drug Price Plan
Sounds like negotiation by press release.
